Chemical structure of molecule RP-3500

ATR kinase inhibitor

phase I/IIa candidate for advanced solid tumors

from lipid-kinase inhibitor scaffold

Molecular Cancer Therapeutics

Repare Therapeutics, Saint-Laurent, CAN

RP-3500 is an oral ATR kinase inhibitor and Ph. II clinical candidate for advanced solid tumors with ATRi-sensitizing mutations, alone or in combination with talazoparib (PARPi) or gemcitabine. Reviewer…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.